Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Alkaloids Stories

2012-06-29 06:16:14

(Ivanhoe Newswire) - An estimated 46 million Americans are current smokers, and approximately 70% of them wish they had never smoked, and want to quit. While it is the 4,000 chemicals within the burning cigarette that causes the health problems associated with smoking, it is the nicotine within the tobacco that keeps the smoker hooked. Researchers at Weill Cornell Medical College have developed and successfully tested in mice an innovative vaccine to treat nicotine addiction. The...

2012-06-06 21:42:30

The discovery of the first enzyme in the pathway sheds new light on the evolution of alkaloid formation Humans encounter alkaloids every day Alkaloids constitute a very large group of natural nitrogen-containing compounds with diverse effects on the human organism. A large variety of plant-produced alkaloids have strong pharmacological effects, and are used as toxins, stimulants, pharmaceuticals or recreational drugs, including caffeine, nicotine, morphine, quinine, strychnine, atropine...

2012-06-04 02:27:12

BATON ROUGE, La., June 4, 2012 /PRNewswire/ -- Esperance Pharmaceuticals presented its Phase 1 study of EP-100, a novel targeted membrane?disrupting peptide (tMDP) in advanced solid tumors at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. EP?100 is designed to seek and destroy cancer cells that over?express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over?expressed in a wide range of cancers. The Phase 1...

2012-06-04 02:26:56

SAN DIEGO, June 4, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced results from a Phase I clinical trial of its lead drug candidate ME-143 in patients with solid refractory tumors. The data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago today. "We are encouraged by the results from this first-in-human study of ME-143,"...

2012-06-02 10:20:13

SEATTLE, June 2, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.  Oncothyreon also provided an update on the status of its ongoing Phase 2 development program for PX-866. Phase 1 Trial of PX-866 in Combination with Docetaxel Data from the Phase 1 portion of...

2012-05-29 10:09:41

Added benefit in men with metastatic hormone-refractory prostate cancer for whom docetaxel is no longer an option Cabazitaxel (trade name: Jevtana®) has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic drug docetaxel. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products” (AMNOG), the German...

2012-05-17 10:25:26

BATON ROUGE, La., May 17, 2012 /PRNewswire/ -- Esperance Pharmaceuticals today announced that it has begun enrollment of a Phase 2, randomized, multi-center trial of EP-100 in combination with paclitaxel for the potential treatment of advanced ovarian cancer. EP-100 is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over-expressed in a wide...

2012-05-03 02:32:03

NEW ORLEANS, May 3, 2012 /PRNewswire-FirstCall/ -- ICU Medical, Inc. (NASDAQ: ICUI) today announced that two studies presented this week at the 37th Annual Congress of the Oncology Nursing Society (ONS) in New Orleans show that the company's ChemoClave(TM) needlefree closed system transfer device (CSTD) protects nurses from accidental exposure to hazardous chemotherapy drugs while increasing nurse satisfaction and perceptions of safety. The ChemoClave system is the world's...

Unmasking Black Pepper's Secrets As A Fat Fighter
2012-05-02 10:53:31

Image Credit: Photos.com A new study provides a long-sought explanation for the beneficial fat-fighting effects of black pepper. The research, published in ACS' Journal of Agricultural and Food Chemistry, pinpoints piperine – the pungent-tasting substance that gives black pepper its characteristic taste, concluding that piperine also can block the formation of new fat cells. Soo-Jong Um, Ji-Cheon Jeong and colleagues describe previous studies indicating that piperine reduces fat...

2012-05-01 06:27:42

EAST SETAUKET, N.Y., May 1, 2012 /PRNewswire/ -- John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc. (LIXT.PK), announced the submission of an IND application to the Food and Drug Administration to conduct a Phase I trial of its lead, anti-cancer compound, LB-100. Dr. Kovach said, "We believe that LB-100, a novel anti-cancer compound, prevents cancer cells from defending themselves against standard types of cancer treatments. In...